TNFα polymorphism as marker of immunosenescence for rheumatoid arthritis patients

Experimental Gerontology

Volumn 61, Issue , 2015, Pages 123-129

  Rodríguez Carrio, Javier ^a   Alperi López, Mercedes ^b   López, Patricia ^a   Alonso Castro, Sara ^b   Ballina García, Francisco J ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

CD4+CD28null cells; Immunosenescence; Rheumatoid arthritis; TNFA polymorphisms

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CD28 ANTIGEN; GENETIC MARKER;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOSENESCENCE; MAJOR CLINICAL STUDY; MALE; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SENESCENCE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; AGING; ANTAGONISTS AND INHIBITORS; GENETIC MARKER; GENETICS; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918777207     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2014.12.009     Document Type: Article

References (39)

1. Atzeni F., Bongiovanni S., Marchesoni A., et al. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine 2014, 81:37-40.
2. Bryl E., Vallejo A.N., Weyand C.M., et al. Down-regulation of CD28 expression by TNF-alpha. J. Immunol. 2001, 167:3231-3238.
3. Cardelli M., Cavallone L., Marchegiani F., et al. A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (A/G)-308 polymorphism. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:454-460.
4. de P.B., Prado C., Alperi-Lopez M., et al. Effects of glucocorticoid treatment on CD25(-)FOXP3(+) population and cytokine-producing cells in rheumatoid arthritis. Rheumatology (Oxford) 2012, 51:1198-1207.
5. del Rincon I.D., Williams K., Stern M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44:2737-2745.
6. Dupont W.D., Plummer W.D. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials 1998, 19:589-601.
7. Fujii H., Shao L., Colmegna I., et al. Telomerase insufficiency in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4360-4365.
8. Goldberg G.L., Zakrzewski J.L., Perales M.A., et al. Clinical strategies to enhance T cell reconstitution. Semin. Immunol. 2007, 19:289-296.
9. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007, 57:125-132.
10. Goronzy J.J., Matteson E.L., Fulbright J.W., et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2004, 50:43-54.
11. Griffiths G.M., Alpert S., Lambert E., et al. Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:549-553.
12. Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
13. Koetz K., Bryl E., Spickschen K., et al. T cell homeostasis in patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9203-9208.
14. Lindstrom T.M., Robinson W.H. Rheumatoid arthritis: a role for immunosenescence?. J. Am. Geriatr. Soc. 2010, 58:1565-1575.
15. Liuzzo G., Kopecky S.L., Frye R.L., et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999, 100:2135-2139.
16. Lopez P., Gomez J., Mozo L., et al. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res. Ther. 2006, 8:R42.
17. + T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997, 40:1106-1114.
18. Maxwell J.R., Potter C., Hyrich K.L., et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum. Mol. Genet. 2008, 17:3532-3538.
19. Nakagawa S., Cuthill I.C. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol. Rev. Camb. Philos. Soc. 2007, 82:591-605.
20. Namekawa T., Wagner U.G., Goronzy J.J., et al. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum. 1998, 41:2108-2116.
21. O'Rielly D.D., Roslin N.M., Beyene J., et al. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009, 9:161-167.
22. - T cells in patients with rheumatoid arthritis. Arthritis Res. Ther. 2003, 5:R210-R213.
23. Rodriguez-Rodriguez L., Gonzalez-Juanatey C., Palomino-Morales R., et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011, 216:125-130.
24. +. J. Immunol. 1998, 161:1018-1025.
25. - T cells in rheumatoid arthritis. Mol. Med. 1996, 2:608-618.
26. - T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 1996, 97:2027-2037.
27. Schonland S.O., Lopez C., Widmann T., et al. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13471-13476.
28. Thewissen M., Linsen L., Somers V., et al. Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann. N. Y. Acad. Sci. 2005, 1051:255-262.
29. Thewissen M., Somers V., Venken K., et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 2007, 123:209-218.
30. null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 2007, 179:6514-6523.
31. Toonen E.J., Barrera P., Fransen J., et al. Meta-analysis identified the TNFA -308 G>A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Res. Ther. 2012, 14:R264.
32. Turesson C., McClelland R.L., Christianson T.J., et al. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:70-75.
33. van Nies J.A., de J.Z., van der Helm-van Mil A.H., et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 2010, 49:2210-2216.
34. Wagner U.G., Koetz K., Weyand C.M., et al. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14447-14452.
35. Ware J.E., Kosinski M., Bayliss M.S., et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med. Care 1995, 33:AS264-AS279.
36. + T cells: reversal by interleukin-12 stimulation. Blood 2003, 101:3543-3549.
37. Weyand C.M., Fulbright J.W., Goronzy J.J. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp. Gerontol. 2003, 38:833-841.
38. Weyand C.M., Fujii H., Shao L., et al. Rejuvenating the immune system in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:583-588.
39. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3195-3199.